Neurotransmitters and neuromodulators released by contraction-activated skeletal 21 muscle afferents into the dorsal horn of the spinal cord initiate the central component of 22 the exercise pressor reflex (EPR). Whether GABA, a major inhibitory neurotransmitter 23 within the mammalian central nervous system, is involved in the modulation of the 24 EPR at the level of dorsal horn remains to be determined. We performed local 25 microinjection of either the GABA(A) antagonist bicuculline or the GABA(B) 26 antagonist CGP 52432 into the ipisilateral L4/L5 dorsal horns to investigate the effect 27 of GABA receptor blockade on the pressor response to either static contraction induced 28 by stimulation of the peripheral end of L4/L5 ventral roots, passive stretch or hindlimb 29 arterial injection of capsaicin (0.1µg/0.2ml) in decerebrate rats. Microinjection of 30 either bicuculline (1 mM, 100 nl) or CGP 52432 (10 mM, 100 nl) into the L4/5 dorsal 31 horns significantly increased the pressor and cardioaccelerator responses to all stimuli. 32 Microinjection of either bicuculline or CGP 52432 into the L5 dorsal horn significantly 33 increased the pressor and cardioaccelerator responses to direct microinjection of 34 L-glutatmate (10 mM, 100 nl) into this spinal segment. The disinhibitory effect of 35 both GABA receptor antagonists on the EPR was abolished by microinjection of the 36 broad spectrum glutamate receptor antagonist, kynurenate (KYN, 10 mM/100 nl). 37 These data suggest that 1) GABA exerts a tonic inhibition of the EPR at the level of 38 dorsal horn; and 2) that an interaction between glutamatergic and GABAergic inputs 39 exist at the level of dorsal horn, contributing to spinal control of the EPR. 40 Key Words: exercise; neurotransmitter; sympathetic nerve activity; blood pressure; 41 decerebration. 42 43
INTRODUCTION
Sigma-Aldrich, St. Louis, MO). Injections were made over a 15-s period, and a 100 nl 153 injection volume was measured by observing the movement of the fluid meniscus 154 along a reticule in the microscope. 155 The GABA A antagonist (-)-bicuculline methiodide (Bic, 0.1 and 1 mM, 156 Sigma-Aldrich, St. Louis, MO), the GABA B antagonist CGP 53432 (CGP, 1 and 10 157 mM, Fisher Scientific Corporation, Pittsburgh, PA), L-glutamate (10 mM, 158 Sigma-Aldrich, St. Louis, MO) and kynurenate (KYN, 10 mM, St. 159 Louis, MO) were dissolved in artificial cerebrospinal fluid. In the case of KYN, pH 160 was adjusted to 7.4-7.6 with 1 M NaOH. The time interval between L4 and L5 161 segment injections was within 2 min. One barrel of a multibarrel pipette was filled 162 with 2% Pontamine sky blue in order to mark the injection site (Figure 1) . The 190 In addition, the cardiovascular response to direct microinjection of L-glutatmate (10 191 mM, 100nl) into the dorsal horn was measured before and 5 min after microinjection 192 of GABA antagonists into the ipsilateral L4 or L5 dorsal horns in decerebrate rats. 194 current study, we found that microinjection of either the GABA A receptor antagonist be a potential therapeutic strategy for preventing or slowing the progression of the 386 exaggerated EPR. Clearly, further work is needed to translate these findings in 387 applicable therapies. In both Bic (1mM) and CGP (10mM) groups, 7 rats were used to perform static 579 contraction whereas the other 7 rats were used to perform passive stretch and 580 administration of capsaicin. 
193

Data Acquisition and Statistical Analysis
